Avoro Capital Advisors LLC Trims Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)

Avoro Capital Advisors LLC cut its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 19.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,910,642 shares of the company’s stock after selling 2,435,036 shares during the quarter. Avoro Capital Advisors LLC owned 3.72% of Autolus Therapeutics worth $23,290,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of AUTL. Jump Financial LLC acquired a new stake in Autolus Therapeutics during the fourth quarter worth about $170,000. Barclays PLC grew its stake in shares of Autolus Therapeutics by 1,094.3% during the 4th quarter. Barclays PLC now owns 11,859 shares of the company’s stock worth $28,000 after purchasing an additional 10,866 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Autolus Therapeutics by 146.7% during the 4th quarter. Renaissance Technologies LLC now owns 618,942 shares of the company’s stock valued at $1,455,000 after purchasing an additional 368,071 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Autolus Therapeutics by 392.0% in the 4th quarter. Legal & General Group Plc now owns 297,736 shares of the company’s stock valued at $697,000 after purchasing an additional 237,224 shares during the period. Finally, HighPoint Advisor Group LLC purchased a new stake in Autolus Therapeutics during the fourth quarter worth $185,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Price Performance

AUTL stock opened at $1.43 on Monday. Autolus Therapeutics plc has a 1 year low of $1.11 and a 1 year high of $5.00. The firm has a market capitalization of $380.51 million, a PE ratio of -1.18 and a beta of 2.06. The business has a 50 day simple moving average of $1.69 and a 200-day simple moving average of $2.54.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $2.98 million. On average, equities research analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AUTL. Truist Financial decreased their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, April 10th. Finally, Wells Fargo & Company lowered their price target on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday, March 21st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $9.32.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.